Use

The Prosigna® assay provides a prognostic gene signature for breast cancer, reporting a 10-year risk of distant recurrence, risk classification, lymph node involvement, tumor size, and proliferative subtype. It is used to guide therapeutic decisions in early-stage breast cancer by assessing the likelihood of disease recurrence and intrinsic subtype profile. Genetic expression of the PAM50 (Prosigna) signature and tumor clinicopathologic features are integrated to inform risk stratification.